• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗疟原虫环子孢子蛋白(CSP)单克隆抗体对疟原虫感染的体外和体内抑制作用。

In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP).

机构信息

Structural Vaccinology Lab, Malaria Biologics Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

出版信息

Sci Rep. 2021 Mar 5;11(1):5318. doi: 10.1038/s41598-021-84622-x.

DOI:10.1038/s41598-021-84622-x
PMID:33674699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7970865/
Abstract

Plasmodium falciparum malaria contributes to a significant global disease burden. Circumsporozoite protein (CSP), the most abundant sporozoite stage antigen, is a prime vaccine candidate. Inhibitory monoclonal antibodies (mAbs) against CSP map to either a short junctional sequence or the central (NPNA) repeat region. We compared in vitro and in vivo activities of six CSP-specific mAbs derived from human recipients of a recombinant CSP vaccine RTS,S/AS01 (mAbs 317 and 311); an irradiated whole sporozoite vaccine PfSPZ (mAbs CIS43 and MGG4); or individuals exposed to malaria (mAbs 580 and 663). RTS,S mAb 317 that specifically binds the (NPNA) epitope, had the highest affinity and it elicited the best sterile protection in mice. The most potent inhibitor of sporozoite invasion in vitro was mAb CIS43 which shows dual-specific binding to the junctional sequence and (NPNA). In vivo mouse protection was associated with the mAb reactivity to the NANPx6 peptide, the in vitro inhibition of sporozoite invasion activity, and kinetic parameters measured using intact mAbs or their Fab fragments. Buried surface area between mAb and its target epitope was also associated with in vivo protection. Association and disconnects between in vitro and in vivo readouts has important implications for the design and down-selection of the next generation of CSP based interventions.

摘要

恶性疟原虫疟疾对全球疾病负担造成了重大影响。环子孢子蛋白(CSP)是最丰富的子孢子阶段抗原,是主要的疫苗候选物。针对 CSP 的抑制性单克隆抗体(mAbs)要么针对短连接序列,要么针对中央(NPNA)重复区。我们比较了六种源自接受重组 CSP 疫苗 RTS,S/AS01 (mAbs 317 和 311)的人类受体的 CSP 特异性 mAbs、来自辐照全子孢子疫苗 PfSPZ 的 mAbs(CIS43 和 MGG4),或暴露于疟疾的个体(mAbs 580 和 663)的体外和体内活性。专门结合(NPNA)表位的 RTS,S mAb 317 具有最高的亲和力,在小鼠中引起最佳的无菌保护。体外抑制子孢子入侵最有效的抑制剂是 mAb CIS43,它对子孢子的连接序列和(NPNA)都具有双重特异性。体内保护与 mAb 对 NANPx6 肽的反应性、对体外入侵活性的抑制、以及使用完整 mAbs 或其 Fab 片段测量的动力学参数相关。mAb 与其目标表位之间的埋藏表面积也与体内保护相关。体外和体内读数之间的关联和不相关对基于 CSP 的下一代干预措施的设计和选择具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/56e2b8256143/41598_2021_84622_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/f725b8e3e116/41598_2021_84622_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/f349b46827c2/41598_2021_84622_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/4a946f4dcfa6/41598_2021_84622_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/31d767f4268f/41598_2021_84622_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/85a3300f2c28/41598_2021_84622_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/a3c0dd1f68eb/41598_2021_84622_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/1f693849bff9/41598_2021_84622_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/56e2b8256143/41598_2021_84622_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/f725b8e3e116/41598_2021_84622_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/f349b46827c2/41598_2021_84622_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/4a946f4dcfa6/41598_2021_84622_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/31d767f4268f/41598_2021_84622_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/85a3300f2c28/41598_2021_84622_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/a3c0dd1f68eb/41598_2021_84622_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/1f693849bff9/41598_2021_84622_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1303/7970865/56e2b8256143/41598_2021_84622_Fig8_HTML.jpg

相似文献

1
In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP).抗疟原虫环子孢子蛋白(CSP)单克隆抗体对疟原虫感染的体外和体内抑制作用。
Sci Rep. 2021 Mar 5;11(1):5318. doi: 10.1038/s41598-021-84622-x.
2
Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.联合单克隆抗体和疫苗对疟原虫环子孢子蛋白的保护作用。
PLoS Pathog. 2021 Dec 6;17(12):e1010133. doi: 10.1371/journal.ppat.1010133. eCollection 2021 Dec.
3
Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies.恶性疟原虫环子孢子蛋白的蛋白水解切割是保护性抗体的作用靶点。
J Infect Dis. 2015 Oct 1;212(7):1111-9. doi: 10.1093/infdis/jiv154. Epub 2015 Mar 11.
4
The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo.恶性疟原虫环子孢子蛋白重复区包含三个不同的表位,这些表位在体内通过抗体保护所必需。
PLoS Pathog. 2021 Nov 8;17(11):e1010042. doi: 10.1371/journal.ppat.1010042. eCollection 2021 Nov.
5
A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.针对 CSP N 端结构域的高亲和力抗体缺乏对疟原虫的抑制活性。
J Exp Med. 2020 Nov 2;217(11). doi: 10.1084/jem.20200061.
6
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.疫苗诱导的针对环子孢子蛋白的单克隆抗体可预防疟原虫感染。
J Clin Invest. 2014 Jan;124(1):140-4. doi: 10.1172/JCI70349.
7
Importance of the Immunodominant CD8 T Cell Epitope of Plasmodium berghei Circumsporozoite Protein in Parasite- and Vaccine-Induced Protection.伯氏疟原虫环子孢子蛋白免疫显性 CD8 T 细胞表位在寄生虫和疫苗诱导保护中的重要性。
Infect Immun. 2020 Sep 18;88(10). doi: 10.1128/IAI.00383-20.
8
IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.针对临床级恶性疟原虫环子孢子蛋白(CSP)疫苗抗原的IgG2抗体与小鼠抵抗转基因子孢子攻击的保护作用相关。
PLoS One. 2014 Oct 24;9(10):e111020. doi: 10.1371/journal.pone.0111020. eCollection 2014.
9
Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.多聚肌苷酸:胞苷酸(Poly(I:C))是一种有效的佐剂,可增强针对恶性疟原虫环子孢子蛋白(CSP)和αDEC-CSP 的抗体和多功能 CD4+ T 细胞反应,在非人类灵长类动物中。
Vaccine. 2010 Oct 21;28(45):7256-66. doi: 10.1016/j.vaccine.2010.08.098. Epub 2010 Sep 21.
10
A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.一种基于单克隆抗体的免疫测定法,用于检测针对恶性疟原虫环子孢子蛋白重复区域的抗体反应。
Malar J. 2016 Nov 8;15(1):543. doi: 10.1186/s12936-016-1596-8.

引用本文的文献

1
Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein.保护性抗体靶向因疟原虫子孢子蛋白裂解而暴露的隐蔽表位。
Science. 2025 Jan 3;387(6729):eadr0510. doi: 10.1126/science.adr0510.
2
Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development.探索恶性疟原虫环子孢子蛋白上的新型表位以用于疫苗开发。
NPJ Vaccines. 2024 Nov 18;9(1):225. doi: 10.1038/s41541-024-01006-8.
3
Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.

本文引用的文献

1
Explicit Treatment of Non-Michaelis-Menten and Atypical Kinetics in Early Drug Discovery*.早期药物发现中对非米氏动力学和非典型动力学的显式处理*。
ChemMedChem. 2021 Mar 18;16(6):899-918. doi: 10.1002/cmdc.202000791. Epub 2020 Dec 28.
2
A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.一种强效抗疟人源单克隆抗体靶向环子孢子蛋白小重复序列并中和肝脏中的孢子。
Immunity. 2020 Oct 13;53(4):733-744.e8. doi: 10.1016/j.immuni.2020.08.014. Epub 2020 Sep 17.
3
IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents.
针对环子孢子蛋白的单克隆抗体作为一种新兴的疟疾预防工具。
Nat Immunol. 2024 Sep;25(9):1530-1545. doi: 10.1038/s41590-024-01938-2. Epub 2024 Aug 28.
4
Malaria vaccines: a new era of prevention and control.疟疾疫苗:预防和控制的新时代。
Nat Rev Microbiol. 2024 Dec;22(12):756-772. doi: 10.1038/s41579-024-01065-7. Epub 2024 Jul 18.
5
Longitudinal analysis of antibody responses to Plasmodium vivax sporozoite antigens following natural infection.自然感染后对间日疟原虫子孢子抗原抗体反应的纵向分析。
PLoS Negl Trop Dis. 2024 Jan 26;18(1):e0011907. doi: 10.1371/journal.pntd.0011907. eCollection 2024 Jan.
6
Exploring genetic polymorphisms among Plasmodium vivax isolates from the Thai-Myanmar borders using circumsporozoite protein (pvcsp) and ookinete surface protein (pvs25) encoding genes.探讨来自泰缅边境间日疟原虫分离株的环子孢子蛋白(pvcsp)和动合子表面蛋白(pvs25)编码基因的遗传多态性。
Parasitol Res. 2024 Jan 11;123(1):91. doi: 10.1007/s00436-023-08104-x.
7
A candidate antibody drug for prevention of malaria.一种预防疟疾的候选抗体药物。
Nat Med. 2024 Jan;30(1):117-129. doi: 10.1038/s41591-023-02659-z. Epub 2024 Jan 2.
8
Comparative analyses of functional antibody-mediated inhibition with anti-circumsporozoite monoclonal antibodies against transgenic Plasmodium berghei.抗环子孢子蛋白单克隆抗体对转基因伯氏疟原虫的功能抗体介导抑制作用的比较分析。
Malar J. 2023 Nov 7;22(1):335. doi: 10.1186/s12936-023-04765-2.
9
Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model.RTS,S/AS01疟疾疫苗的保护性抗体阈值与小鼠模型中的抗原和佐剂剂量相关。
NPJ Vaccines. 2023 Aug 10;8(1):114. doi: 10.1038/s41541-023-00714-x.
10
A multivalent circumsporozoite protein-based nanoparticle malaria vaccine elicits a robust and durable antibody response against the junctional epitope and the major repeats.一种基于多价环子孢子蛋白的纳米颗粒疟疾疫苗可引发针对连接表位和主要重复序列的强烈且持久的抗体反应。
Bioeng Transl Med. 2023 Mar 28;8(4):e10514. doi: 10.1002/btm2.10514. eCollection 2023 Jul.
IMRAS-一种用活的、经过辐射减毒的疟原虫孢子虫进行蚊虫叮咬免疫的临床试验:免疫参数对保护效力的影响和免疫试剂库的建立。
PLoS One. 2020 Jun 17;15(6):e0233840. doi: 10.1371/journal.pone.0233840. eCollection 2020.
4
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.抗疟原虫环子孢子蛋白重复基序的保护性人抗体的进化。
Nat Med. 2020 Jul;26(7):1135-1145. doi: 10.1038/s41591-020-0881-9. Epub 2020 May 25.
5
Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein.评价两种体内挑战模型以测量针对恶性疟原虫环子孢子蛋白的单克隆抗体的功能活性。
Malar J. 2020 Mar 17;19(1):113. doi: 10.1186/s12936-020-03181-0.
6
Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein.单克隆抗体与恶性疟原虫环子孢子蛋白连接表位结合的结构与机制。
PLoS Pathog. 2020 Mar 9;16(3):e1008373. doi: 10.1371/journal.ppat.1008373. eCollection 2020 Mar.
7
Optimization of a circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform.利用烟草花叶病毒平台优化环子孢子蛋白重复疫苗。
Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):3114-3122. doi: 10.1073/pnas.1911792117. Epub 2020 Jan 27.
8
Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein.疟原虫环子孢子蛋白保守结构基序的多样化抗体反应。
J Mol Biol. 2020 Feb 14;432(4):1048-1063. doi: 10.1016/j.jmb.2019.12.029. Epub 2019 Dec 27.
9
Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages.优化体内模型以研究疟原虫红前期免疫。
Malar J. 2019 Dec 18;18(1):426. doi: 10.1186/s12936-019-3055-9.
10
Quantification of wild-type and radiation attenuated Plasmodium falciparum sporozoite motility in human skin.定量检测人皮肤中野生型和辐射减毒疟原虫孢子运动能力。
Sci Rep. 2019 Sep 17;9(1):13436. doi: 10.1038/s41598-019-49895-3.